JB Pharma registers impressive numbers for FY2021-22

JB Pharma has registered impressive numbers for the Financial Year (FY) 2021-22 and the Q1 of the current financial year with a growth rate more than 25 per cent, outperforming the market rate of 18 per cent (IQVIA, MAT Jun’22). The company has also registered operating revenues at Rs 2,424 crore and EBITDA at Rs 550 crore, a statement from the company has notified.

Speaking on the performance of the company, Nikhil Chopra, CEO and Whole Time Director, JB Pharma said in the statement, “Our growth has been nothing less than outstanding for the year 2021-22, being ranked in the top 23 pharmaceutical companies in India. We plan on moving quickly up to No. 20, outperforming all market expectations, with strong showing in our domestic business, especially in the core therapy areas.”

He further added, “Our domestic business has shown significant momentum with the launch of our new Go-to-Market model which has helped us increase productivity bringing greater focus to domestic business. Our entry into the fast-growing chronic segments like heart failure, diabetes and nephrology, along with the launch of 15 new products in the year has helped push up our share of domestic sales in new products by more than five per cent. We will continue to consolidate our new acquisitions with the current portfolio and geographical strengths of JB Pharma, towards consistently delivering market beating growth.”